Testing effectiveness (Phase 2)Study completedNCT01396382What this trial is testing68Ga-DOTATATE PET Scan in Neuroendocrine CancerWho this might be right forNeuroendocrine Carcinoma Vanderbilt-Ingram Cancer Center 97
Testing effectiveness (Phase 2)Study completedNCT01229943What this trial is testingEverolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by SurgeryWho this might be right forAdvanced Pancreatic Neuroendocrine TumorLocally Advanced Pancreatic Neuroendocrine TumorPancreatic Gastrinoma+3 more National Cancer Institute (NCI) 150
Early research (Phase 1)Study completedNCT03849469What this trial is testingXmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsWho this might be right forMelanomaCervical CarcinomaPancreatic Carcinoma+20 more Xencor, Inc. 78
Testing effectiveness (Phase 2)Temporarily pausedNCT06202066What this trial is testingTemozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasWho this might be right forDigestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid Neoplasm+1 more Roswell Park Cancer Institute 60
Early research (Phase 1)Study completedNCT00073944What this trial is testingBCX-1777 in Treating Patients With Refractory CancerWho this might be right forCancer BioCryst Pharmaceuticals
Early research (Phase 1)Study completedNCT00006368What this trial is testingYttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerWho this might be right forBrain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid Tumor+5 more Novartis Pharmaceuticals 60
Testing effectiveness (Phase 2)Study completedNCT04068896What this trial is testingStudy of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyWho this might be right forPancreatic CancerMetastatic Castration-resistant Prostate CancerBladder Cancer+8 more NGM Biopharmaceuticals, Inc 89
Not applicableLooking for participantsNCT03452774What this trial is testingSYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryWho this might be right forCancer, MetastaticCancerCancer of Pancreas+40 more Massive Bio, Inc. 50,000
Not applicableStudy completedNCT00477919What this trial is testingE-MOSAIC Electronic Tool to Monitor SymptomsWho this might be right forCancer Swiss Cancer Institute 264
Early research (Phase 1)Ended earlyNCT02313012What this trial is testingSafety and PK Study of CC-90003 in Relapsed/Refractory Solid TumorsWho this might be right forNeoplasm Metastasis Celgene 19
Testing effectiveness (Phase 2)Study completedNCT02893930What this trial is testingSapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryWho this might be right forPancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma National Cancer Institute (NCI) 13
Early research (Phase 1)Active Not RecruitingNCT05907304What this trial is testingAssess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsWho this might be right forAdvanced or Metastatic Solid Tumors Erasca, Inc. 86
Testing effectiveness (Phase 2)UnknownNCT05627427What this trial is testingMulti-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyWho this might be right forNeuroendocrine Tumor Grade 3Neuroendocrine CarcinomaPancreatic Carcinoma Tianjin Medical University Cancer Institute and Hospital 60
Testing effectiveness (Phase 2)Study completedNCT00075439What this trial is testingGefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsWho this might be right forGastrinomaGlucagonomaInsulinoma+6 more National Cancer Institute (NCI) 90
Early research (Phase 1)WithdrawnNCT06626256What this trial is testingSTIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWho this might be right forLocally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid Neoplasm+24 more City of Hope Medical Center
Not applicableStudy completedNCT05461430What this trial is testingMass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)Who this might be right forPleural Effusion, MalignantAscites, MalignantCarcinoma+29 more Travera Inc 72
Early research (Phase 1)Study completedNCT01300533What this trial is testingBIND-014 Given to Patients With Advanced or Metastatic CancerWho this might be right forMetastatic CancerCancerSolid Tumors BIND Therapeutics 58
Testing effectiveness (Phase 2)Ended earlyNCT03207867What this trial is testingNIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaWho this might be right forNSCLC, Non Small Cell Lung CancerRCC, Renal Cell CancerPancreatic Cancer+7 more Novartis Pharmaceuticals 315
Early research (Phase 1)Active Not RecruitingNCT05215574What this trial is testingStudy of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsWho this might be right forPancreatic CancerBreast CancerGastric Cancer+13 more NGM Biopharmaceuticals, Inc 130
Early research (Phase 1)Looking for participantsNCT05076760What this trial is testingMEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsWho this might be right forSolid TumorAdvanced CancerMetastatic Cancer+7 more Memgen, Inc. 40